Zhen Fan

List of Publications by Year
in descending order

43 papers	3,510 citations	172457 29 h-index	254184 43 g-index
43 all docs	43 docs citations	43 times ranked	5425 citing authors

#	Article	IF	Citations
1	Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2022, 71, 1611-1623.	4.2	2
2	ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamineâ€addicted OSCC cells. Cancer Medicine, 2020, 9, 3489-3499.	2.8	20
3	Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma. JCI Insight, 2019, 4, .	5.0	25
4	Functional cooperation between HIF-1Î± and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR. Lung Cancer, 2018, 121, 82-90.	2.0	21
5	Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNÎ³ secretion. Cancer Letters, 2018, 430, 47-56.	7.2	117
6	AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. Cancer Letters, 2017, 408, 33-42.	7.2	31
7	Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab. Cancer Letters, 2017, 384, 39-49.	7.2	63
8	ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer Letters, 2016, 381, 23-30.	7.2	51
9	Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Letters, 2016, 373, 36-44.	7.2	135
10	Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNÎ³ secretion. OncoImmunology, 2016, 5, e1100790.	4.6	46
11	Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget, 2016, 7, 64766-64777.	1.8	22
12	AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget, 2015, 6, 11507-11518.	1.8	29
13	Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biology and Therapy, 2014, 15, 89-98.	3.4	12
14	A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells. Cancer Letters, 2013, 335, 380-386.	7.2	33
15	HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain. Cellular Signalling, 2013, 25, 1754-1761.	3.6	16
16	Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. Cancer Biology and Therapy, 2013, 14, 237-245.	3.4	32
17	Cetuximab Reverses the Warburg Effect by Inhibiting HIF-1â€"Regulated LDH-A. Molecular Cancer Therapeutics, 2013, 12, 2187-2199.	4.1	67
18	The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1Î±. Cancer Letters, 2012, 322, 78-85.	7.2	47

#	Article	IF	Citations
19	Resveratrol-Activated AMPK/SIRT1/Autophagy in Cellular Models of Parkinson's Disease. NeuroSignals, 2011, 19, 163-174.	0.9	405
20	Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor–targeted therapy with cetuximab and gefitinib. Cancer Letters, 2011, 306, 85-91.	7.2	10
21	Differential Turnover of Myosin Chaperone UNC-45A Isoforms Increases in Metastatic Human Breast Cancer. Journal of Molecular Biology, 2011, 412, 365-378.	4.2	27
22	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell, 2010, 18, 423-435.	16.8	129
23	The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1α and Bcl-2 and Activating the Beclin 1/hVps34 Complex. Cancer Research, 2010, 70, 5942-5952.	0.9	172
24	Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy, 2010, 6, 1066-1077.	9.1	87
25	1, 9-Pyrazoloanthrones Downregulate HIF-1α and Sensitize Cancer Cells to Cetuximab-Mediated Anti-EGFR Therapy. PLoS ONE, 2010, 5, e15823.	2.5	16
26	Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab. Molecular Cancer Therapeutics, 2008, 7, 1207-1217.	4.1	59
27	Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab. Cancer Research, 2007, 67, 8240-8247.	0.9	149
28	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α. Molecular Cancer, 2007, 6, 63.	19.2	55
29	Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine. Molecular Pharmacology, 2006, 70, 1045-1052.	2.3	48
30	Autophosphorylation of Akt at Threonine 72 and Serine 246. Journal of Biological Chemistry, 2006, 281, 13837-13843.	3.4	25
31	The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene, 2005, 24, 4433-4441.	5.9	120
32	Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Research, 2005, 7, R589-97.	5.0	75
33	C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1163-1173.	0.8	49
34	The epidermal growth factor receptor mediates radioresistance. International Journal of Radiation Oncology Biology Physics, 2003, 57, 246-254.	0.8	272
35	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene, 2003, 22, 3205-3212.	5.9	406
36	Sensitization of breast cancer cells to radiation by trastuzumab. Molecular Cancer Therapeutics, 2003, 2, 1113-20.	4.1	189

#	Article	IF	Citations
37	Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clinical Cancer Research, 2002, 8, 1253-64.	7.0	70
38	C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. International Journal of Radiation Oncology Biology Physics, 2001, 51, 474-477.	0.8	136
39	Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate, 2001, 47, 21-28.	2.3	32
40	Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 2001, 20, 1913-1922.	5.9	107
41	The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene, 2001, 20, 3726-3734.	5.9	40
42	Antitumor effect of an HER2â€specific antibodyâ€"toxin fusion protein on human prostate cancer cells. Prostate, 2001, 47, 21-28.	2.3	2
43	Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene, 2000, 19, 2423-2429.	5.9	61